Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40356 | 1.00 | PTGS2 (0.53) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL1405603 | 0.88 | CA1 (0.65) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL1405602 | 0.88 | CA1 (0.65) | PTGS2CA12CA1CA2CA7 | |
| SCHEMBL3223 | 0.85 | — | — | |
| SCHEMBL10598384 | 0.83 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27088448 | 0.83 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20913241 | 0.83 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28139275 | 0.83 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28768515 | 0.83 | CA1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21242229 | 0.81 | KMT2A (0.57) | PTGS2CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | claimed |
| EP-2177522-B1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU PHARMA CO LTD (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-8318716-B2 | Carbapenem derivatives | KBP BIOSCIENCES CO., LTD. (CN) | 2012-11-27 | — | — | US | disclosed |
| US-8293895-B2 | Carbapenem derivatives | KBP BIOSCIENCES CO., LTD. (CN) | 2012-10-23 | — | — | US | disclosed |
| US-20110160177-A1 | NOVEL CARBAPENEM DERIVATIVES | XUANZHU (HAINAN) BIOPHARMACEUTICAL CO., LTD. (CN) | 2011-06-30 | — | — | US | disclosed |
| US-20100197653-A1 | NOVEL CARBAPENEM DERIVATIVES | KBP BIOSCIENCES CO., LTD. (CN) | 2010-08-05 | — | — | US | disclosed |
| EP-2177522-A1 | NOVEL CARBAPENEM DERIVATIVES | KBP Biosciences Co., Ltd. (CN) | 2010-04-21 | — | — | EP | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7012083-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20050234102-A1 | Substituted pyrazoles | CAI HUI | 2005-10-20 | — | — | US | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| US-20020099214-A1 | Compounds useful in therapy | PFIZER INC. (US) | 2002-07-25 | — | — | US | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| US-3956219-A | DIVINYLBENZENE | ELI LILLY AND COMPANY (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099214-A1 | Compounds useful in therapy | HRH2, ITCH, HRH4 | PTGS2 268/4885CA12 1665/4885CA1 2269/4885 |
| US-20110160177-A1 | NOVEL CARBAPENEM DERIVATIVES | MGAM, RPIA, MGAM2 | PTGS2 3769/4885CA12 1567/4885CA1 4515/4885 |
| US-20100197653-A1 | NOVEL CARBAPENEM DERIVATIVES | SI, MGAM, IDE | PTGS2 3695/4885CA12 1628/4885CA1 3255/4885 |
| US-20050234102-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | PTGS2 2448/4885CA12 1780/4885CA1 890/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | PTGS2 2077/4885CA12 4644/4885CA1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.